Original-Research: SYGNIS AG - von GBC AG
Einstufung von GBC AG zu SYGNIS AG
Unternehmen: SYGNIS AGISIN: DE000A1RFM03
Anlass der Studie: Research CommentEmpfehlung: BUYKursziel: 4,05 EURKursziel auf Sicht von: End FY 2015Letzte Ratingänderung: Analyst: Cosmin Filker, Felix Gode
Positive news flow about the direct marketing strategy; furtherdistribution agreements closed and new product launched After the successful placement of the capital increase in December 2014(gross proceeds of issue: EUR4.95 million), SYGNIS AG implemented a seriesof measures for marketing its own product pipeline. As part of the newbusiness strategy, which focuses on more intensive use of marketingpotential, the company presented the first own product line in November2014 with TruePrime(TM). The technology which the company has developeditself and incorporated into TruePrime(TM) makes it possible to amplify theentire genome from tiny sample quantities of up to individual cells. Inaddition, TruePrime(TM) technology markedly reduces the occurrence ofartefacts in DNA copying. The first product in this product line was launched in January 2015 withthe introduction of the TruePrime(TM) Single Cell WGA KIT. The plan is touse various distribution channels as part of worldwide direct marketing tointensively exploit the marketing potential. Along with marketing via the newly introduced SYGNIS TruePrime(TM) onlineshop, the company will draw on a range of specialised distributors. Itannounced the signing of non-exclusive distribution agreements for thispurpose. International partnerships have already been established with theGerman BioCat GmbH, the Spanish bioNova cientifica, s.l. the French OZYMEFrance and the Canadian D-MARK BIOSCIENCES. Furthermore, the second-largestmarket for life science products is being addressed through the most recentdistribution agreement with the Japanese company FUNAKOSHI Co. Ltd. Thesedistribution agreements are particularly interesting because they cover allfuture products in the TruePrime(TM) family and therefore offer potentiallyhigh economies of scale. This has laid a foundation for the expected salessuccess of the TruePrime(TM) Single Cell WGA KIT at an early stage. We areanticipating further dynamic expansion of the distribution network. In addition to this, introduction of the second product in theTruePrime(TM) product line was announced on 23/02/2015. The new productTruePrime(TM) WGA Kit amplifies DNA and the entire genome from various celltypes and limited sample volumes whilst maintaining a similarly highquality. SYGNIS AG will also be using established distribution channels forthese products. In view of recent successes in expanding the distribution network and inproduct development, we think SYGNIS AG is making good progress inoperational terms. As these assumptions remain unchanged, we will maintainour target price of EUR4.05 and reaffirm our BUY rating.
Die vollständige Analyse können Sie hier downloaden:http://www.more-ir.de/d/12745.pdf
Kontakt für RückfragenJörg GrunwaldVorstandGBC AGHalderstraße 2786150 Augsburg0821 / 241133 0research@gbc-ag.